Arvinas LLC(ARVN) - 2024 Q4 - Annual Results

Exhibit 99.1 Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update – Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – Vepdegestrant: Oral PROTAC ER degrader • Announced that the VERITAC-2 Phase 3 monotherapy clinical trial evaluating vepdegestrant in ER+/HER2- metastatic breast cancer remains on track, with topline data anticipated in 1Q25 (ClinicalTrials.gov Identifier: NCT05654623). • Announced plans to initiate t ...